Wall Street Prep – Biotech Sum of the Parts Valuation

About Course:
What You Will Learn

Market size and model potential revenue for a therapeutic asset in clinical development
Road-map the path to commercialization for a biotech through the FDA approval process
Apply the appropriate “probability of success”” to a clinical-stage pre-revenue biotech company
Apply key assumptions and tie together a long-range forecast of multiple products with a DCF analysis

Biotech Sum of the Parts Valuation

Biotech SOTP welcome
Biotech SOTP introduction
Course Downloads
Overview of a sum of the parts valuation
Major building blocks for a biotech SOTP
Model assumptions dashboard
Biotech company lifecycle
Identify peak revenue opportunity
Therapeutic areas overview
Product launch timing and uptake curve
Patent life and loss of exclusivity
Road to commercialization
FDA clinical trials
Building a commercial infrastructure
Completing the SOTP
Probability of success
Build out one part of the SOTP (Product #1)
Finalizing the valuation model
Valuation sensitivities
Example: Blueprint Medicines Corp
Biotech SOTP Course Review